Psych Investor (@Kukeon2022) header
Psych Investor (@Kukeon2022) profile picture

If you die before you die, You won't die when you die. -The Immortality Key

Joined February 2022
Photo by Psych Investor (@Kukeon2022)Photo by Psych Investor (@Kukeon2022)Photo by Psych Investor (@Kukeon2022)Photo by Psych Investor (@Kukeon2022)Photo by Psych Investor (@Kukeon2022)Photo by Psych Investor (@Kukeon2022)Photo by Psych Investor (@Kukeon2022)Photo by Psych Investor (@Kukeon2022)Photo by Psych Investor (@Kukeon2022)
Psych Investor retweeted
APPROACH Phase 3 Topline Study Results $HELP Link: ir.helus.com/static-files/1c…
1
10
690
Psych Investor retweeted
Helus Pharma today announced positive topline results from APPROACH, its Phase 3 pivotal study evaluating HLP003 as an adjunctive treatment for adults with major depressive disorder. Learn more: ir.helus.com/news-releases/n… ↩️
7
8
33
2,147
Psych Investor retweeted
Helus Pharma will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder. Learn more: shorturl.at/1NF0m ↩️
3
10
2
51
4,981
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026 $HELP globenewswire.com/news-relea…
1
5
1
33
3,611
Psych Investor retweeted
LSD as a longevity therapy? LSD pushes brain gene activity in the opposite direction of aging In rodents, the effect was stronger than exercise LSD activated gene networks involved in neuroplasticity and neuronal communication, and reduced amyloid-β damage
167
164
49
1,708
126,188
Psych Investor retweeted
Compass Files Psilocybin for TRD New Drug Application with FDA This morning, Compass Pathways announced the submission of its COMP360 psilocybin for treatment-resistant depression (TRD) new drug application (NDA). Read more on our website: psychedelicalpha.com/news/br…
3
8
2
37
5,755
From the @InvestorStream_ desk: 📢 @Entropy_Neuro (#ASX: $ENP) secures South African patent for proprietary psilocin formulations through 2043 ⚡ Strengthens TRP-8803's IP protection, supporting future licensing & strategic partnerships #biotech #health youtube.com/shorts/SVMj5KlyA…
2
2
142
🔬Entropy Neurodynamics secured a South African patent for proprietary psilocin crystalline forms, strengthening the IP portfolio supporting TRP-8803. Protection extends to September 2043. Read more: asx.api.cmfyapp.com/asx-rese… #ASX $ENP #Biotech
3
4
201
@Solvonis (LSE: SVNS) receives USPTO Notice of Allowance for its method-of-use patent covering ketamine across all behavioural addictions. First priorities: binge eating and gambling disorders. Grant expected Q1 2027; term to May 2042. Investigational. 🔗solvonis.com/news/behavioura… $SVNS
1
2
178
Psych Investor retweeted
This morning, Compass Pathways shared its Q3 2026 results, which included an update on its COMP360 psilocybin for treatment-resistant depression (TRD) new drug application (NDA) submission. “Final NDA submission nearing completion”, the release states, “and will be filed in the next two weeks.”
2
8
40
2,294
Psych Investor retweeted
Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston. The fireside chat will be webcast live on Monday, November 9, 2026 at 3:00 p.m. EDT. Learn more and register for the webcast here: shorturl.at/y0yQw
1
17
980
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights $CMPS ir.compasspathways.com/News-…
1
25
1,404